Skip Navigation LinksHome > October 2010 - Volume 58 - Issue 7 > Infliximab Reduces the Frequency of Interleukin 17-Producing...
Journal of Investigative Medicine:
doi: 10.231/JIM.0b013e3181eb9895
Brief Report

Infliximab Reduces the Frequency of Interleukin 17-Producing Cells and the Amounts of Interleukin 17 in Patients With Rheumatoid Arthritis

Shen, Hui PhD; Xia, Liping PhD; Lu, Jing PhD; Xiao, Weiguo PhD

Collapse Box


Background: To detect frequency changes in interleukin 17 (IL-17)+ CD4+ T cells and the amounts of IL-17 in supernatants between baseline and 30 weeks after Infliximab combined with methotrexate (MTX) or MTX-alone therapy.

Methods: Flow cytometry was used to analyze the frequency of IL-17+ CD4+ T cells in rheumatoid arthritis (RA) patients and control subjects at baseline and 30 weeks after therapy. Secretion of IL-17 by peripheral blood mononuclear cells was measured by enzyme-linked immunosorbent assay.

Results: The percentages of IL-17+ CD4+T cells were increased in the peripheral blood mononuclear cells of patients with RA compared with healthy subjects. The percentages of IL-17+ CD4+T cells were correlated with the number of swelling joints and C-reactive protein of RA patients. Likewise, concentrations of IL-17 in supernatants from patients with RA were significantly higher compared with those from control subjects. After infliximab combined with MTX or MTX-alone therapy, the number of swelling joints, erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, and Disease Activity Score 28 decreased significantly compared with baseline. Only in the infliximab + MTX group that the frequency of TH17 cells and concentration of IL-17 decreased.

Conclusions: These data support the hypothesis that infliximab therapy can have an effect on TH17 cells and decrease disease activity.

© 2010 American Federation for Medical Research


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.